Login to Your Account

Another Rare Disease Play for Pfizer

Zacharon Inks Potential $210M Glycan-Targeting Drug Alliance

By Jennifer Boggs

Friday, April 8, 2011
A small biotech boasting a technology aimed at targeting difficult-to-drug glycans and a big pharma firm continuing to make inroads in the orphan disease space came together in an early stage deal to develop small molecules against lysosomal storage disorders (LSDs) such as mucopolysaccharidoses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription